74733-30-5

Basic information

• Product Name: METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE
• Synonyms: METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE;Benzoic acid, 4-(broMoMethyl)-3-chloro-, Methyl ester;4-(BroMoMethyl)-3-chlorobenzoic acid Methyl ester
• CAS NO: 74733-30-5
• Molecular Formula: C₉H₈BrClO₂
• Molecular Weight: 263.52
• Mol File: 74733-30-5.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE(74733-30-5)
• EPA Substance Registry System: METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE(74733-30-5)

Safety Data

• Hazardous Substances Data: 74733-30-5(Hazardous Substances Data)

Usage

General Description

Methyl 4-(bromomethyl)-3-chlorobenzoate is a chemical compound with the molecular formula C9H8O2BrCl. It is a white to off-white solid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. METHYL 4-(BROMOMETHYL)-3-CHLOROBENZOATE is a derivative of benzoic acid and contains both bromine and chlorine atoms, making it useful for various organic reactions. It is important to handle this compound with care, as it may cause skin and eye irritation and should only be used in well-ventilated areas. With its versatile reactivity and potential applications, methyl 4-(bromomethyl)-3-chlorobenzoate is an important compound in the field of organic chemistry.

Upstream product

• 56525-63-4 methyl 3-chloro-4-methyl-benzoate 
• 615-62-3 3-chloro-4-methylphenol 
• 5162-82-3 3-chloro-4-methylbenzoic acid 

Downstream Products

• 104447-88-3 3-Chloro-4-[6-(2-ethyl-hexanoylamino)-indol-1-ylmethyl]-benzoic acid methyl ester 
• 467442-06-4 (±)-methyl 3-chloro-4-(cyanomethyl)benzoate 
• 940062-11-3 4-aminomethyl-3-chlorobenzoic acid methyl ester 
• 916913-67-2 methyl 3-chloro-4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 165528-69-8 4-(tert-Butyloxycarbonylaminomethyl)-3-chlorobenzoic Acid 
• 479234-92-9 (4-aminomethyl-3-chloro-phenyl)-(5,6,7,8-tetrahydro-thieno[3,2-b]azepin-4-yl)-methanone 
• 785040-42-8 [2-chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzyl]-carbamic acid tert-butyl ester 
• 479234-76-9 (2S,4R)-1-[2-Chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzylcarbamoyl]-4-methoxy-pyrrolidine-2-carboxylic acid methyl ester 
• 479234-81-6 (2S,4R)-1-[2-Chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzylcarbamoyl]-4-methoxy-pyrrolidine-2-carboxylic acid 
• 484648-97-7 4-(2-{[(2S)-2-amino-4,4-difluorobutanoyl]amino}ethyl)-3-chlorobenzoate 
• 484648-98-8 methyl 4-{2-[((2S)-2-{[(benzyloxy)carbonyl]amino}-4,4-difluorobutanoyl)amino]-ethyl}-3-chlorobenzoate 
• 484648-99-9 methyl 4-{2-[((2S)-2-{[N-(tert-butoxycarbonyl)-L-leucyl]amino}-4,4-difluorobutanoyl)amino]-ethyl}-3-chlorobenzoate 

Relevant articles and documents

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME

Compound represented by formula (I): wherein each symbol is as defined herein, exhibit TRPA1 antagonist activity, and are useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Histone Deacetylase Inhibitors

This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).